Pulse Biosciences, Inc. (PLSE) is a novel bioelectric medicine company dedicated to improving the lives of patients battling a variety of conditions. The company is committed to progress clinical applications that address significant unmet medical needs and carries forward vast potential in immuno-oncology.
Founded in 2014 and based in Hayward, California, Pulse Biosciences, Inc is focused on developing and commercializing a platform using its proprietary "Nano-Pulse Stimulation" (NPS) technology. The NPS is a non-thermal, precise and localized technology that opens up new doors for medical advances. It’s designed to initiate cell death in the treatment of various types of solid tumors while sparing neighboring healthy tissue, hence becoming an innovative solution in the healthcare industry.
Pulse Biosciences, Inc places a significant emphasis on research and development. Their primary research focus revolves around using NPS technology to treat dermatological and aesthetic conditions as well as solid tumors. The company also examines the utility of NPS in additional applications, such as cardiac ablation and veterinary care.
The NPS technology platform by Pulse Biosciences has demonstrated encouraging results in several early trials in humans and animals. It has also been positively received by the scientific community, with many leading experts supportive of its potential.
One of the prominent applications of the NPS technology is CellFXTM, aimed at dermatology and aesthetics conditions. The CellFXTM system is used in procedures addressing sebaceous glands responsible for several dermatologic conditions such as sebaceous hyperplasia, acne, and skin rejuvenation.
Despite being relatively young, Pulse Biosciences, Inc has made a notable impact in the bioscience industry. The company’s mission of creating a distinct, clinically superior, operator-independent and patient-friendly tissue treatment methodology through its NPS technology is commendable. The diligence and commitment of Pulse Biosciences to continue its research and development efforts while maintaining its patient-focused mission symbolize a highly promising future for the company in the medical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study for benign thyroid nodules, presented at the American Thyroid Association Annual Meeting. The study showed that 86% of patients achieved at least 50% nodule volume reduction after a single nonthermal nsPFA treatment, with significant improvements in symptoms and quality of life and no serious adverse events. The nPulse™ Vybrance™ Percutaneous Electrode System offers a nonthermal, ultrasound-guided option that preserves critical structures and provides same-day discharge for patients.
Pulse Biosciences (PLSE) announced the early completion of enrollment for its NanoPulse AF pivotal IDE study, finishing three months ahead of schedule with 169 evaluable patients. The company reported a strong cash position of $189 million, providing approximately two years of cash runway, bolstered by over $150 million raised through its ATM program. Despite a GAAP net loss of $23.1 million in Q3 2026, Pulse Biosciences remains confident in its launch readiness, scaling manufacturing, and differentiated nanosecond PFA technology, which CEO Paul LaViolette believes offers superior clinical outcomes and procedural efficiency compared to current microsecond PFA devices.
Pulse Biosciences announced business updates and financial results for the third quarter ended September 30, 2026, highlighting the completion of enrollment for its NANOPULSE-AF US IDE pivotal study three months ahead of schedule. The company reported $189 million in cash, cash equivalents, and marketable securities, reflecting a significant strengthening of its balance sheet. Pulse Biosciences is now focusing on launch readiness, additional data readouts, and regulatory submissions for its nPulse Cardiac Catheter System.
Pulse Biosciences Inc (NASDAQ: PLSE) is showing a mid-channel oscillation pattern with strong near-term sentiment potentially leading to a long-term positive bias. AI models have generated three trading strategies—Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT)—tailored to different risk profiles. The analysis highlights an exceptional risk-reward short setup targeting 15.8% downside with minimal risk.
Pulse Biosciences announced that its NANOPULSE-AF Study has successfully reached its enrollment target of 164 evaluable patients across 15 clinical sites, three months ahead of schedule. The study is evaluating the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant atrial fibrillation. The rapid enrollment highlights significant investigator interest and the system's efficient procedural workflow.